EP4619032A1 - Bait vaccines - Google Patents
Bait vaccinesInfo
- Publication number
- EP4619032A1 EP4619032A1 EP23818626.6A EP23818626A EP4619032A1 EP 4619032 A1 EP4619032 A1 EP 4619032A1 EP 23818626 A EP23818626 A EP 23818626A EP 4619032 A1 EP4619032 A1 EP 4619032A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bait
- formulation
- matrix
- bait formulation
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/26—Compounds containing phosphorus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the claimed invention was made as a result of activities undertaken within the scope of a joint research agreement between Zoetis LLC and IREC (UCLM-CSIC).
- This invention is generally in the field of bait vaccines for the protection of wild boars.
- Eurasian wild boar (Sus scrofa) is a natural reservoir of several pathogens shared with humans and with farm animals, and therefore effective disease control is necessary to mitigate the consequences caused by the presence of shared infections (Ballesteros et al., 2007). Oral vaccination has great potential to control infections in wild reservoirs and prevent outbreaks in other species (Muller et al., 2012). In Europe, and in the specific case of wild boar, first field tests were carried out in the 1990s to control Classical Swine Fever (CSF) and oral vaccination of wild boar against CSF was later expanded to different European countries (Delegated regulation UE 2020/689). For this process, different factors must be considered, such as an early deployment of vaccination, the structure of the landscape and spatial distribution of food sources, and professional support to work alongside hunters and wildlife and forestry agencies (Rossi et al., 2015).
- CSF Classical Swine Fever
- Vaccines can seek contact with the oropharyngeal mucosa (Ballesteros et al., 2007) or seek to cross the gastric barrier without the acids and enzymes inactivating the antigen, to reach the intestine.
- the latter can be achieved in two ways, one by lipid composition baits (Aldwell et al., 2003), as fats are attacked by bile acids in the small intestine, and alternatively by capsules or other protective containers that dissolve in the intestine (Mahato et al., 2003). African swine fever vaccines would most likely target the oral mucosa (Sang et al., 2020).
- Precedent baits include the RIEMSER® one for classical swine fever vaccination (Kaden et al., 2000), the Australian PIGOUT® Feral Pig Bait used for delivery of toxicants to feral pigs in Australia and the USA (Cowled et al., 2006), and the IREC bait used for oral vaccination against animal tuberculosis in Spain (Ballesteros et al., 2009).
- RIEMSER® baits have a low melting point (30°C), and its shape and texture can make the bait difficult to handle and lead to vaccine loss (Rossi et al., 2015). In addition, this bait is too large to be consumed by wild boars under4 months of age (Faust et al., 2007).
- the PIGOUT® bait requires high temperatures in the extrusion process for its production (Beltran-Beck et al. 2013).
- IREC bait proposed by Ballesteros et al. was designed to contain 0.2 ml polyethylene capsules to introduce the vaccine formulation. These baits use paraffin (melting point 51-53°C) as cement and were found suitable for field application during summer with relatively high temperatures (up to 44 ? C, Beltran-Beck et al., 2014). However, these baits have a limited resistance to humidity (Ballesteros et al., 2009) and are not species-specific (Ballesteros et al., 2011; Beltran-Beck et al., 2014).
- Baits have been administered through numerous deployment strategies such as by air from planes or helicopters (Kaden et al., 2002), burying them to specifically target wild boar and protect the live vaccine from damage due to high temperatures (Kaden et al., 2002), through selective piglet feeders (Ballesteros et aL, 2009), or deploying the baits under heavy stones which wild boar can lift (Diez-Delgado et al., 2019). Airborne bait deployment is particularly suited for interventions over large areas (Siers et al., 2017). However, I REC type baits have never been deployed from aircraft and assessments of bait resistance are lacking.
- a bait vaccine formulation for swine comprising: a. an antigen, b. optionally, an adjuvant, c. a matrix, wherein said antigen is inside of a container, wherein said container is entirely within the matrix, wherein the matrix is not coated by a protective film, wherein said bait formulation is i) temperature stable and/or ii) humidity stable and/or iii) suitable for aerial deployment.
- the matrix comprises corn flour, piglet feed, sugar, and a binder, wherein said piglet feed comprises from about 30% w/w to about 42% w/w barley, from about 30% w/w to about 35% w/w wheat, from about 9% w/w to about 11% w/w soy flour, from about 3% w/w to about 10% peas, from about 2% w/w to about 8% wheat bran, from about 1% w/w to about 7% w/w corn gluten, and from about 1.5% to about 3% w/w fatty acids.
- said corn flour is present at about 14% w/w to about 22% w/w of said matrix, said piglet feed is present at about 35% w/w to about 45% w/w of said matrix, said sugar is present at about 12% w/w to about 18 % w/w of said matrix, and said binder is present at about 24% w/w to about 28 % w/w of said matrix.
- said corn flour is present at about 17% w/w of said matrix
- said piglet feed is present at 40-42% w/w of said matrix
- said sugar is present at 14-16% w/w of said matrix
- said binder is present at 24- 26% w/w of said matrix.
- the antigen is inside a container, and wherein said container is entirely within the matrix.
- the bait is generally oblong shape, wherein the longest dimension is at least 1.8 times greater than the second-longest dimension and wherein said longest dimension is between about 2.5 cm and about 6 cm.
- said bait vaccine formulation has a generally semi-spherical shape, wherein the longer dimension is about 2.5 to about 3.6 cm and the shorter dimension is about 1 to about 1.7 cm.
- said formulation is weight-stable at 25-42 °C.
- said formulation is humidity-stable.
- said formulation is suitable for aerial deployment.
- the antigen is selected from the group consisting of antigens protecting from infections selected from the group consisting of African swine fever virus, classical wine fever virus, Aujeszky's disease virus and Mycobacterium tuberculosis complex and any combination thereof.
- the antigen is an ASF antigen.
- said bait vaccine formulation is black, green, or blue-colored.
- the instant disclosure provides a method of eliciting protective immune response against a pathogen in a wild boar or feral pig population in a habitat, the method comprising placing the bait formulation of according to any of the embodiments of the first aspect of the invention in said habitat, wherein the antigen elicits protective response from said infection.
- said bait formulations are deployed aerially.
- the instant disclosure provides a use of the bait formulation according to any embodiments of the first aspect for eliciting protective immune response against a pathogen in a wild boar or feral pig.
- said bait formulation is deployed aerially.
- antigen refers to any substance that is recognized by the animal's immune system and generates an immune response.
- the term includes killed, inactivated, attenuated, or modified live bacteria, viruses, or parasites.
- antiigen also includes polynucleotides, polypeptides, recombinant proteins, synthetic peptides, protein extract, cells (including tumor cells), tissues, polysaccharides, or lipids, or fragments thereof, individually or in any combination thereof.
- antigen also includes antibodies, such as anti-idiotype antibodies or fragments thereof, and to synthetic peptide mimotopes that can mimic an antigen or antigenic determinant (epitope).
- the term "humidity-stable” refers to changes in weight of the bait formulation after said bait formulation was no more than 7% submerged into water for 72 hours at 25°C to 42°C.
- the formulation is humidity stable if under the conditions above its weight changed by no more than 5% compared to the weight before the test.
- the weight of the humidity-stable formulation changes by no more than 4%, or no more than 3%, or no more than 2%, or no more than 1%.
- the term "oblong shape” refers to shapes having a longer and shorter dimension and where the cross section is about the same or less than the shorter dimension.
- the longest dimension is at least 1.8 times greater than the second-longest dimension.
- the longer dimension is from 1.8 to 2.5 times greater than the second longer dimension, including, without limitations about 1.9 times, 2 times, 2.1 times, 2.2 times, 2.3 times, and 2.4 times.
- the edges of the oblong shape are rounded for an easier consumption.
- the oblong shape may be in a form of a prism, cylinder, or ellipsoid shape.
- the oblong shape is hemispherical, with dimensions of about 2.5 to about 4 cm by about 1 to about 2 cm.
- suitable for aerial deployment refers to displacement of less than 8 mm, measured as provided in the Example.
- pathogen is used together with the antigen. Briefly, the antigen is capable of eliciting the protective immune response against the respective pathogen.
- the term "protective immune response” refers to a reduction in an intensity or a duration of at least one clinical symptom of an infection with a given pathogen. Clinical symptoms vary depending on the nature of the pathogen and may include, without limitations, fever, diarrhea, lung lesions, nasal shedding, oral shedding fecal shedding, and other symptoms. Preferably, the protective immune response prevents the infection of the vaccinated animal with the pathogen.
- the protective immune response may be measured directly or inferred by immunological endpoints, including markers of cell-mediated immune system as well as protective antibody titers.
- the term "vaccine” refers to a composition containing an antigen, wherein the composition elicits the protective immune response against the respective pathogen.
- the invention provides a bait vaccine formulation for swine, the formulation comprising: an antigen; optionally, an adjuvant; and a matrix, wherein said antigen is inside of a container, wherein said container is entirely within the matrix, wherein the matrix is not coated by a protective film, wherein said bait formulation is temperature-stable and/or humidity-stable and/or suitable for aerial deployment.
- the matrix of the bait comprises corn flour, piglet feed, sugar, and a binder.
- the binder is honey or sugar cane molasses. More preferably, the binder is honey.
- said corn flour is present at about 14% w/w to about 22% w/w of said matrix
- said piglet feed is present at about 35% w/w to about 45% w/w of said matrix
- said sugar is present at about 12% w/w to about 18 % w/w of said matrix
- said binder is present at about 24% w/w to about 28 % w/w of said matrix.
- said corn flour is present at about 14% w/w to 21% w/w of said matrix
- said piglet feed is present at about 35% w/w to 43% w/w of said matrix
- said sugar is present at about 12% w/w to about 18 % w/w of said matrix
- said binder e.g., honey
- said corn flour is present at about 17% w/w of said matrix
- said piglet feed is present at 40-42% w/w of said matrix
- said sugar is present at 14-16% w/w of said matrix
- honey is present at 24-26% w/w of said matrix.
- the piglet feed comprises from about 30% w/w to about 42% w/w barley, from about 30% w/w to about 35% w/w wheat, from about 9% w/w to about 11% w/w soy flour, from about 3% w/w to about 10% peas, from about 2% w/w to about 8% wheat bran, from about 1% w/w to about 7% w/w corn gluten, and from about 1.5% to about 3% w/w fatty acids.
- w/w percentage in application to the piglet feed, the percentages are given in relationship to the total composition of the piglet feed rather than the total composition of the bait matrix.
- the piglet feed may also contain minerals such as copper, vitamins (e.g., vitamin A and vitamin D3), amino acids (such as polylysine) and sodium chloride.
- the piglet feed comprises about 37% w/w barley, about 32% w/w wheat, about 10.5% w/w soy flour, about 6% w/w peas, about 5% w/w wheat bran, about 4% w/w corn gluten, about 2.3% w/w fatty acids, and further comprises about 1.2% w/w di-calcium phosphate, about 1.1% w/w calcium carbonate, about 0.5% w/w minerals, vitamin A, vitamin D3, copper, lysine, and sodium chloride (about 0.4% w/w).
- Natural beeswax has been used as a superhydrophobic coating (Li et aL, 2018).
- the inventors observed that wild boar tended to break coated baits, consuming the exposed matrix. This is undesired because it might lead to the loss of the Eppendorf tube and therefore a vaccination failure. Accordingly, it is preferred that the baits disclosed herein do not contain any coatings.
- the corn flour is present at about 17% w/w of said matrix
- said sugar is present at 14-16% w/w of said matrix
- honey is present at 24.5-25.5% w/w of said matrix
- said piglet feed is present at 40-42% w/w of said matrix, wherein said piglet feed comprises about 37% w/w barley, about 32% w/w wheat, about 10.5% w/w soy flour, about 6% w/w peas, about 5% w/w wheat bran, about 4% w/w corn gluten, about 2.3% w/w fatty acids, and further comprises about 1.2% w/w di-calcium phosphate, about 1.1% w/w calcium carbonate, about 0.5% w/w minerals, vitamin A, vitamin D3, copper, lysine, and about 0.4% sodium chloride.
- the baits of the invention are generally oblong, including cylindrical, semicylindrical, hemispheric, ellipsoid, oval, hemi-ellipsoid, prism-shape and so on. It is preferred that the angles of these shapes are rounded for an easier consumption. It is preferred that the bait should be generally hemispheric.
- the dimensions of the bait are limited by the size of the animals. It is currently preferred that the long dimension should be about 2.5 to about 6 cm, and the shorter dimension should be 1.8-2.5 times less than the longer dimension.
- the bait is of a hemispheric shape, wherein the longer dimension is about 2.9 to about 3.8 cm and the shorter dimension is about 1 to about 1.8 cm. In the most preferred embodiments, the bait is of a hemispheric shape, wherein the longer dimension is about 2.9 to about 3.5 cm and the shorter dimension is about 1 to about 1.5 cm.
- the baits of the invention generally possess at least one of the following properties -they are temperature-resistant, they are humidity-resistant, and/or they are suitable for aerial deployment. In more preferred embodiments, at least two of these properties are present, and in even more preferred embodiments, all three properties are present.
- the temperature-stable baits of the invention do not change weight after 72 hours at a temperature ranging from 25°C to 42°C, and particularly at the temperature ranging from 37°C to 42 °C.
- the humidity-stable baits of the invention do not change weight after being about 7% submerged in water for up to 72 hours.
- the exposure to temperature of 4°C to 42°C for up to 48°C and humidity do not affect the impact resistance of the baits of the invention.
- the matrix of the bait contains the container which holds the antigen(s) and optional adjuvant(s). It is preferred that the container be fully within the matrix.
- the volume of the container should be sufficient to contain the antigen(s) and the optional adjuvant(s).
- the volume of the container may vary between about 1 ml and about 0.1 ml, including, without limitations, about 0.2 ml, about 0.3 ml, about 0.4 ml, about 0.5 ml, about 0.6 ml, about 0.7 ml, about 0.8 ml, about 0.9 ml. In certain embodiments, applicable to any baits described herein, the volume of the container is about 0.2 ml.
- Containers may be biodegradable or not biodegradable. Suitable non-limiting materials for the container include without limitations cellulose, PLA/PGA polymers, and plastic. In certain embodiments, the container is EPPENDORF® vial.
- antigens are suitable for administration via baits.
- the most suitable antigens can elicit the protective immune response against pathogens that affect wild boar and feral pig populations and that can be transmitted to farmed pigs.
- the pathogens include, without limitations, African Swine Fever virus, Classical Swine Fever virus, Pseudorabies virus.
- the pathogen may be of bacterial or protozoan origin, including, without limitations, members of the Mycobacterium tuberculosis complex and other mycobacteria, Lawsonia intracellularis, giardia, Cryptosporidium spp, and other pathogens.
- Both monovalent vaccines (antigens against one pathogen) and multivalent vaccines (antigens against multiple pathogens) may be present in the container.
- the antigens may be present in the form of inactivated pathogens (for example, inactivated bacteria, inactivated viruses, bacterins), modified live pathogens, subunits and DNA vaccines. The combinations of these antigens are also possible.
- the container may also include optional adjuvants.
- adjuvants Multiple adjuvants are known in the field and the choice of the adjuvant would depend on the nature of the antigens. Suitable adjuvants include, without limitations, Aluminum compounds, mycobacterium cell walls, saponin (including its complexes with sterols and/or phospholipids such as, for example ISCOM®), lipopolysaccharides, poly l:C, CpG-containing immunostimulatory oligonucleotides, glycolipids, liposomes. Different combinations of these adjuvants are also possible.
- the contents of the container may include mucoadhesives, carriers, antibiotics, antiparasitic drugs, other medicaments, buffers, preservatives and the like.
- the baits of the invention may be deployed by multiple methods. For example, in the habitats where the wild pigs' diets are supplemented by feed, such as corn or piglet feed, the baits may be left with the corn or the piglet feed. In other embodiments, the baits may be left in places known to be frequented by pigs, e.g., near farm fields or on pigs' tracks. Other methods, such as areal deployment, deployment in piglet-selective feeding cages, and deployment under heavy stones, are also possible.
- Aerial bait deployment has proven successful in fox rabies control in Europe (Muller et al., 2012). Baiting from aircraft has also been used to control certain species with toxic baits, such as possums (Trichosurus vulpecula) in New Zealand (Morgan, 2010), feral cats (Felis Silvestris) and red foxes in Australia (Moseby et al., 2011), or invasive brown tree snakes Boiga irregularis) in Guam (Goetz et al., 2021). However, none of the previously existing wild boar baits has been tested for their suitability for aerial deployment.
- the inventors simulated areal deployment using compression tests thus measuring the displacement that could be caused by a collusion of the bait with the ground.
- the displacements were greater than 8 mm, it was considered that the impact plane collided with the container comprising the antigen and the optional adjuvant. This collision could lead to fracture.
- the new bait formulation resists impact from a maximum altitude of 500 meters.
- the bait formulation is resistant to being dispersed from about 100 to 500 meters above the ground, or about 200 to 500 meters above the ground, or about 300 to 500 meters above the ground, or about 400 to 500 meters above the ground, or about 100 to about 400 meters above the ground, or about or about 200 to about 300 meters above the ground.
- the starting point was the IREC bait, which was designed to contain 0.2 ml polyethylene capsules to introduce the vaccine formulation. Baits were prepared with a matrix containing 44% piglet feed, 22% wheat flour, 16.5% paraffin (Dilabo SA, Madrid, Spain), 16.5% sucrose, and 1% cinnamon and truffle attractant in powder (Norel SA, Madrid, Spain) (Ballesteros et al., 2009). Different components and protective films were tested to improve the mechanical properties of the bait and its endurance to ambient temperature and humidity. Ultimately, the improved bait matrix composition included 41% piglet feed (Piensos Inalsa, Ciudad Real, Spain), 17% corn flour, 15% sucrose, and 25% honey. Honey acted as cement instead of using paraffin. Both the IREC and the new bait contain, in the center of the bait matrix, a 200 pl Eppendorf tube (VWR, Pennsylvania, USA) to carry the target vaccine or substance. [0057] Palatability trials
- vanilla-cinnamon-truffle Norel S.A., Madrid, Spain
- anise PME Cake, Riverwalk Business Park, UK
- almond PME Cake, Riverwalk Business Park, UK
- cadaverine >97.0% GC, Sigma-Aldrich, Darmstadt, Germany
- colorants black, green and blue; Wilton Brands LLC, Illinois, USA
- the baits were weighed and allowed to fall from an altitude of 5 meters hitting on a concrete surface. The procedure was repeated up to 15 attempts per bait, and the number of impacts against the ground that the baits withstood without losing the Eppendorf tubes was recorded.
- SolidWorks CAD software SolidWorks Corp., Dassault Systemes, Suresnes, France. Compression tests were carried out using an electro-mechanical universal testing machine from the Instron company (Instron 5696, Illinois Tool Works Inc., Glenview, Illinois, United States), a device equipped with a 1 kN load cell and compressive platens. The load is applied with a constant displacement rate of 5 mm/min.
- DIC 3D Digital Image Correlation
- the Poisson ratio (v) was obtained as the ratio between the strains £ yy and s xx , which are the strains in the transverse (y-direction) and longitudinal (x- direction) averaged in the region of interest:
- the elastic modulus (Young's modulus) is the slope of the stress-strain curve in the linear region, calculated by linear regression. Finally, the yielding strength was obtained as the stress level at the onset of nonlinearity in the stress-strain curve.
- Table 1 presents the results of seven palatability trials with captive wild boar. While none of the trials resulted in statistically significant differences between prototypes, several relevant insights were gained. First, importantly, the average times to bait detection and bait consumption were almost identical regardless of the bait matrix tested, IREC vs. new formulation, indicating that the new formulation would not reduce bait uptake rates. Baits were (expectably) detected at the same time regardless their shape, but it took the wild boar double the time to consume the spherical baits, which tended to roll away. Furthermore, wax coating presence/absence and bait flavor and color were irrelevant for bait detection and consumption by wild boar. The cadaverine flavor was not tested because it was difficult to introduce in the bait matrix.
- Table 1 summarizes palatability trials in captive wild boar. Results of seven trials are presented, testing the effects of the presence/absence of a wax coating, spherical vs. hemispherical bait shape, different flavors (vs. plain baits), and black coloring (vs. no colorant), indicating the number of baits per trial group, number of repeats, and average time to detection and time to consumption, in minutes, with their standard error.
- Tria s Species visiting baits (in %) and bait consumption rates per species (in %) during field trials with the new bait formulation. Tria s consisted of 10 baiting sites with 20 baits per site.
- Table 4 Comparison of the effects of humidity on bait weight and impact resistance between the new bait formulation and the IREC bait.
- Table 5 Comparison of the effects of temperature on bait weight and impact resistance between the new bait formulation and the IREC bait.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263426386P | 2022-11-18 | 2022-11-18 | |
| PCT/US2023/079532 WO2024107660A1 (en) | 2022-11-18 | 2023-11-13 | Bait vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4619032A1 true EP4619032A1 (en) | 2025-09-24 |
Family
ID=89121498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP23818626.6A Pending EP4619032A1 (en) | 2022-11-18 | 2023-11-13 | Bait vaccines |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4619032A1 (en) |
| JP (1) | JP2025538464A (en) |
| KR (1) | KR20250089559A (en) |
| CN (1) | CN120202018A (en) |
| AU (1) | AU2023382491A1 (en) |
| CL (1) | CL2025001460A1 (en) |
| CO (1) | CO2025006990A2 (en) |
| MX (1) | MX2025005809A (en) |
| TW (1) | TWI877894B (en) |
| WO (1) | WO2024107660A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106107124A (en) * | 2016-06-28 | 2016-11-16 | 白会娟 | A kind of antitoxin the feed for piglet and preparation method thereof |
-
2023
- 2023-11-09 TW TW112143193A patent/TWI877894B/en active
- 2023-11-13 KR KR1020257018521A patent/KR20250089559A/en active Pending
- 2023-11-13 AU AU2023382491A patent/AU2023382491A1/en active Pending
- 2023-11-13 EP EP23818626.6A patent/EP4619032A1/en active Pending
- 2023-11-13 CN CN202380079606.6A patent/CN120202018A/en active Pending
- 2023-11-13 WO PCT/US2023/079532 patent/WO2024107660A1/en not_active Ceased
- 2023-11-13 JP JP2025528688A patent/JP2025538464A/en active Pending
-
2025
- 2025-05-16 CL CL2025001460A patent/CL2025001460A1/en unknown
- 2025-05-16 MX MX2025005809A patent/MX2025005809A/en unknown
- 2025-05-27 CO CONC2025/0006990A patent/CO2025006990A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023382491A1 (en) | 2025-05-22 |
| WO2024107660A1 (en) | 2024-05-23 |
| CN120202018A (en) | 2025-06-24 |
| JP2025538464A (en) | 2025-11-28 |
| KR20250089559A (en) | 2025-06-18 |
| CL2025001460A1 (en) | 2025-08-22 |
| MX2025005809A (en) | 2025-06-02 |
| TWI877894B (en) | 2025-03-21 |
| TW202425818A (en) | 2024-07-01 |
| CO2025006990A2 (en) | 2025-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tompkins et al. | Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums | |
| Maki et al. | Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review | |
| Buddle et al. | Update on vaccination of cattle and wildlife populations against tuberculosis | |
| Ruyra et al. | Targeting and stimulation of the zebrafish (Danio rerio) innate immune system with LPS/dsRNA-loaded nanoliposomes | |
| Olsen | Brucellosis in the United States: role and significance of wildlife reservoirs | |
| Corner et al. | Oral vaccination of badgers (Meles meles) with BCG and protective immunity against endobronchial challenge with Mycobacterium bovis | |
| Ballesteros et al. | Evaluation of baits for oral vaccination of European wild boar piglets | |
| Johnston et al. | An aerial baiting system for the distribution of attenuated or recombinant rabies vaccines for foxes, raccoons, and skunks | |
| Suwanbumrung et al. | Oral delivery of a Streptococcus agalactiae vaccine to Nile tilapia (Oreochromis niloticus) using a novel cationic-based nanoemulsion containing bile salts | |
| Knobel et al. | Development of a bait and baiting system for delivery of oral rabies vaccine to free-ranging African wild dogs (Lycaon pictus) | |
| Thangsunan et al. | Novel development of cationic surfactant-based mucoadhesive nanovaccine for direct immersion vaccination against Francisella noatunensis subsp. orientalis in red tilapia (Oreochromis sp.) | |
| Bhattacharya et al. | Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease | |
| Ballesteros et al. | Specificity and success of oral-bait delivery to Eurasian wild boar in Mediterranean woodland habitats | |
| Tompkins et al. | Sustained protection against tuberculosis conferred to a wildlife host by single dose oral vaccination | |
| Kern et al. | Live-vaccinia virus encapsulation in pH-sensitive polymer increases safety of a reservoir-targeted Lyme disease vaccine by targeting gastrointestinal release | |
| Moreira et al. | Amyloodiniosis in aquaculture: A review | |
| Blancou et al. | Options for the control of disease 1: targeting the infectious or parasitic agent | |
| Cross et al. | Lipid-formulated BCG as an oral-bait vaccine for tuberculosis: vaccine stability, efficacy, and palatability to brushtail possums (Trichosurus vulpecula) in New Zealand | |
| Relimpio et al. | Improved stability and specificity of baits for oral administration of substances to wild boar | |
| EP4619032A1 (en) | Bait vaccines | |
| CN107205953B (en) | Compositions and methods for reducing zoonotic infectious diseases | |
| Jojola et al. | Oral rabies vaccine (ORV) bait uptake by captive striped skunks | |
| Palmer et al. | Testing a molasses-based bait for oral vaccination of white-tailed deer (Odocoileus virginianus) against Mycobacterium bovis | |
| Bergman et al. | Bait acceptability for delivery of oral rabies vaccine to free-ranging dogs on the Navajo and Hopi Nations | |
| Bryant et al. | Effect of viral respiratory vaccine treatment on performance, health and carcass traits of auction-origin feeder steers. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20250610 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40125573 Country of ref document: HK |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) |